{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T05:08:31Z","timestamp":1739509711855,"version":"3.37.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/meg.0b013e3283110198","type":"journal-article","created":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T09:46:50Z","timestamp":1257932810000},"page":"1407-1412","source":"Crossref","is-referenced-by-count":4,"title":["Peginterferon\/ribavirin treatment achieves a higher compliance rate than interferon\/ribavirin combination in patients chronically infected with HCV on methadone maintenance"],"prefix":"10.1097","volume":"21","author":[{"given":"Dimitrios","family":"Dimitroulopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elefteria","family":"Petroulaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spilios","family":"Manolakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domna","family":"Tsaklakidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Xinopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klisthenis","family":"Tsamakidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tzourmakliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouel","family":"Paraskevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210207","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-14-20210207","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/hep.1840360705","article-title":"The burden of hepatitis C in the United States","volume":"36","author":"Kim","year":"2002","journal-title":"Hepatology"},{"key":"R3-14-20210207","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S0168-8278(03)00008-4","article-title":"Management of hepatitis C","volume":"38","author":"Alberti","year":"2003","journal-title":"J Hepatol"},{"key":"R4-14-20210207","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2105\/AJPH.91.1.46","article-title":"Prevalence and duration of hepatitis C among injection drug users in San Francisco, California","volume":"91","author":"Lorvick","year":"2001","journal-title":"Am J Public Health"},{"key":"R5-14-20210207","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"key":"R6-14-20210207","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/qjmed\/94.3.153","article-title":"Managing chronic hepatitis C acquired through intravenous drug use","volume":"94","author":"Jowett","year":"2001","journal-title":"Q J Med"},{"key":"R7-14-20210207","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"R8-14-20210207","first-page":"956","article-title":"Consensus Statement.","volume":"30","author":"EASL International Consensus Conference on Hepatitis","year":"1999","journal-title":"J Hepatol"},{"key":"R9-14-20210207","first-page":"S71","article-title":"National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C","volume":"26","year":"1997","journal-title":"Hepatology"},{"key":"R10-14-20210207","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1002\/hep.1840360727","article-title":"Prevention and treatment of hepatitis C in injection drug users","volume":"36","author":"Edlin","year":"2002","journal-title":"Hepatology"},{"key":"R11-14-20210207","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJM200107193450311","article-title":"Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?","volume":"345","author":"Edlin","year":"2001","journal-title":"N Engl J Med"},{"key":"R12-14-20210207","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","article-title":"American Gastroenterological Association technical review on the management of hepatitis C","volume":"130","author":"Dienstag","year":"2006","journal-title":"Gastroenterology"},{"key":"R13-14-20210207","first-page":"55","article-title":"Treatment of hepatitis C viral infection in substance abusers","volume":"68","author":"Robaeys","year":"2005","journal-title":"Acta Gastroenterol Belg"},{"key":"R14-14-20210207","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","article-title":"Treatment of chronic hepatitis C in patients with drug dependence. Is time to change the rules?","volume":"99","author":"Schaefer","year":"2004","journal-title":"Addiction"},{"key":"R15-14-20210207","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0149-2918(02)80065-0","article-title":"Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b","volume":"24","author":"Neri","year":"2002","journal-title":"Clin Ther"},{"key":"R16-14-20210207","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in methadone maintenance patients: an interim analysis","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"R17-14-20210207","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.06.002","article-title":"The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone","volume":"39","author":"Sylvestre","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"R18-14-20210207","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0002-9270(03)00708-1","article-title":"Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse","volume":"98","author":"Van Thiel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R19-14-20210207","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatology"},{"key":"R20-14-20210207","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","article-title":"Correlates of hepatitis C virus infections among injection drug users","volume":"74","author":"Thomas","year":"1995","journal-title":"Medicine (Baltimore)"},{"key":"R21-14-20210207","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/oxfordjournals.aje.a009792","article-title":"Syringe exchange and risk of infection with hepatitis B and C viruses","volume":"149","author":"Hagan","year":"1999","journal-title":"Am J Epidemiol"},{"key":"R22-14-20210207","first-page":"S3","article-title":"National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"R23-14-20210207","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"R24-14-20210207","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","article-title":"Hepatitis C treatment in difficult-to-treat psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects","volume":"46","author":"Schaefer","year":"2007","journal-title":"Hepatology"},{"key":"R25-14-20210207","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R26-14-20210207","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"}],"container-title":["European Journal of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042737-200912000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:17:34Z","timestamp":1739423854000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-200912000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0b013e3283110198","relation":{},"ISSN":["0954-691X"],"issn-type":[{"type":"print","value":"0954-691X"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}